title: Aminophylline for methotrexate-induced neurotoxicity.
abstract: Methotrexate, a mainstay treatment for children with acute lymphoblastic leukaemia, can cause neurotoxicity, with paralysis, seizures, somnolence, anorexia, and headaches. The pathophysiology of this reaction is unknown. It has been suggested that the anti-inflammatory effect of methotrexate in patients with arthritis is due to adenosine release brought on by inhibition of purine synthesis. Since adenosine is a central nervous system depressant, we wondered whether adenosine release in the central nervous system could account for some of the neurotoxicity due to methotrexate, and whether that toxicity could be lessened by displacement of adenosine from its receptor by aminophylline. 6 patients (age 3-16 years) who had methotrexate-induced neurotoxicity unresponsive to standard treatment received 2.5 mg/kg aminophylline. In addition, the concentration of adenosine in the cerebrospinal fluid (CSF) from 11 children completing a 24-h systemic methotrexate protocol was compared with that in 8 newly diagnosed patients and 12 who had not received any treatment for at least a week. 4 of 6 patients with toxic signs and symptoms attributed to methotrexate and unrelieved by steroids, epidural blood patch, promethazine, 5-hydroytryptamine antagonists, paracetamol, and narcotics, had complete resolution of neurotoxicity after or during a 1-h infusion of aminophylline; 2 others had a pronounced improvement but persistent nausea. CSF adenosine concentrations of patients receiving methotrexate, even when there was very slight or no toxicity, were greatly increased compared with control subjects (mean values of 217 and 51 nmol/L, median 175 and 52 nmol/L). Subacute methotrexate neurotoxicity may be mediated by adenosine and relieved by aminophylline.
authors.affiliation: Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Bernini
authors.forename: D W
authors.initials: DW
authors.lastname: Fort
authors.forename: J C
authors.initials: JC
authors.lastname: Griener
authors.forename: B J
authors.initials: BJ
authors.lastname: Kane
authors.forename: W B
authors.initials: WB
authors.lastname: Chappell
authors.forename: B A
authors.initials: BA
authors.lastname: Kamen
mesh_terms: D000241:Adenosine / Q000134:cerebrospinal fluid; D000293:Adolescent; D000628:Aminophylline / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000134:cerebrospinal fluid / Q000139:chemically induced / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000134:cerebrospinal fluid / Q000188:drug therapy
chemical_list: D000628:Aminophylline; D000241:Adenosine; D008727:Methotrexate